Literature DB >> 1438107

Views of a general population on mass screening for colorectal cancer: the Burgundy Study.

P Arveux1, G Durand, C Milan, L Bedenne, D Lévy, B D Doan, J Faivre.   

Abstract

BACKGROUND: The success of a screening program depends on a number of factors, including the validity of the test, its efficacy, its feasibility, and the rate of compliance. Thus, it is important to determine the factors influencing compliance to the screening test in order to obtain a high participation rate.
METHODS: A mass screening campaign for colorectal cancer using the Hemoccult test was conducted in Burgundy, France. One year later, a questionnaire was mailed to a random sample of the population to assess the views of the general public (870 persons who had not completed the Hemoccult test, 750 persons who had a negative test, and 100 persons who had a positive test). The compliance rate of this survey was 32.2% among persons who had not completed the screening test, 88.2% among persons with a negative result, and 98.0% among persons with a positive result.
RESULTS: The main reason for not participating was not wanting to know more about their health status (34.3%). Of the factors credited with encouraging persons to perform the test, the most important ones were the practitioner's explanations (55.7%) and the leaflet sent by mail (42.5%). The impact of the media campaign was weak. A small portion of the population (4.3%) said that they were very anxious while waiting for the results. Among persons with a positive screening test, only 1.2% regretted having taken it. Among those who took the test, 94.2% said they were ready to do it again; and among those who did not take it, 36.7% would accept it at a second screening.
CONCLUSIONS: The data suggest that overall the Hemoccult is well accepted, that the campaign did not upset the population, and that it is worthwhile at the second screening to include those who did not participate in the first screening test.

Entities:  

Mesh:

Year:  1992        PMID: 1438107     DOI: 10.1016/0091-7435(92)90065-p

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  7 in total

1.  Estimating the efficacy and efficiency of cascade genetic screening.

Authors:  M Krawczak; D N Cooper; J Schmidtke
Journal:  Am J Hum Genet       Date:  2001-06-26       Impact factor: 11.025

2.  Acceptance of flexible sigmoidoscopy as a screening examination for colorectal cancer in an outpatient clinic.

Authors:  S Gölder; W Vogt; H Lichti; H C Rath; A Kullmann; J Schölmerich; F Kullmann
Journal:  Int J Colorectal Dis       Date:  2006-07-04       Impact factor: 2.571

3.  Knowledge and perceptions of colorectal cancer screening among urban African Americans.

Authors:  K Allen Greiner; Wendi Born; Nicole Nollen; Jasjit S Ahluwalia
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

4.  Implementation intentions and colorectal screening: a randomized trial in safety-net clinics.

Authors:  K Allen Greiner; Christine M Daley; Aaron Epp; Aimee James; Hung-Wen Yeh; Mugur Geana; Wendi Born; Kimberly K Engelman; Jeremy Shellhorn; Christina M Hester; Joseph LeMaster; Daniel C Buckles; Edward F Ellerbeck
Journal:  Am J Prev Med       Date:  2014-11-18       Impact factor: 5.043

5.  Psychosocial variables associated with colorectal cancer screening in South Australia.

Authors:  Stephen R Cole; Ian Zajac; Tess Gregory; Sarah Mehaffey; Naomi Roosa; Deborah Turnbull; Adrian Esterman; Graeme P Young
Journal:  Int J Behav Med       Date:  2011-12

6.  Beliefs associated with fecal occult blood test and colonoscopy use at a worksite colon cancer screening program.

Authors:  Usha Menon; Victoria L Champion; Gregory N Larkin; Terrell W Zollinger; Priscilla M Gerde; Sally W Vernon
Journal:  J Occup Environ Med       Date:  2003-08       Impact factor: 2.162

7.  American Indian perceptions of colorectal cancer screening: viewpoints from adults under age 50.

Authors:  Melissa K Filippi; Stacy Braiuca; Lance Cully; Aimee S James; Won S Choi; K Allen Greiner; Christine M Daley
Journal:  J Cancer Educ       Date:  2013-03       Impact factor: 2.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.